Enhancing immunotherapy response in melanoma: myeloid-derived suppressor cells as a therapeutic target

Despite the remarkable success of immune checkpoint inhibitors (ICIs) in melanoma treatment, resistance to them remains a substantial clinical challenge. Myeloid-derived suppressor cells (MDSCs) represent a heterogeneous population of myeloid cells that can suppress antitumor immune responses mediat...

Descripción completa

Detalles Bibliográficos
Autores principales: Ozbay Kurt, Feyza Gul, Lasser, Samantha, Arkhypov, Ihor, Utikal, Jochen, Umansky, Viktor
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10313369/
https://www.ncbi.nlm.nih.gov/pubmed/37395271
http://dx.doi.org/10.1172/JCI170762

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10313369/
https://www.ncbi.nlm.nih.gov/pubmed/37395271
http://dx.doi.org/10.1172/JCI170762

Ejemplares similares